TEVA trade ideas
Teva finishing accumulation stage.Price under but close to Volume profile (POI). I think it is good time to open short position.
TEVA- I have a bad feeling about this oneIt already had a horrible reaction to Earnings. Sure looks like this is falling out of favor.
WARREN BUFFETT INCREASES STAKE IN TEVA TO 4.3%NEWS - 2 DAYS AGO
Billionaire investor Warren Buffett increased his stake in Teva Pharmaceutical Industries to 4.3% during the second quarter of 2018, according to the quarterly financial statement from his investments firm Berkshire Hathaway. ... Altogether its stake is worth $957 million, according to Teva's closing price on Tuesday.
TEVA HAS A STRONG PIPELINE OF NEW DRUGS COMING TO MARKET
TEVA WINS FDA APPROVAL - EPIPEN FOR PEDIATRIC CHILDRENA MUST READ ARTICLE!!
The FDA Approval is "NOT" just for adults. FDA also gave TEVA approval to administer the EPIPEN to PEDIATRIC CHILDREN
arstechnica.com
Pediatric Sub-population
Approximate Age Range
Newborn - birth to 1 month of age
Infant - 1 month to 2 years of age
Child - 2 to 12 years of age
Adolescent - 12-21 years of age
This opens up a whole new Sales Market / Revenue Stream for TEVA and the Generic Epipen.
FOOD ALLERGY RESEARCH GROUP (FARE)
How Many People Have Food Allergies?
Researchers estimate that up to 15 million Americans have food allergies, including 5.9 million children under age 18. That’s 1 in 13 children, or roughly two in every classroom.
About 30 percent of children with food allergies are allergic to more than one food.
Food Allergies Are on the Rise
The Centers for Disease Control & Prevention reports that the prevalence of food allergy in children increased by 50 percent between 1997 and 2011.
Between 1997 and 2008, the prevalence of peanut or tree nut allergy appears to have more than tripled in U.S. children.
Possible bounce on $TEVAteva has pulled back now for 3 days, we can possibly have a bounce off the 50MA, if this turns out to b the case, then this would result in the 21MA crossing above the 50MA which signals a bullish move, manage risk. GLTA
Teva still positive but...$Teva is still positive in the uptrend although the candle of yesterday has turned some indicators in bearish position. Over the mid term bullish trend is still strong. Having said that next candles have to be monitored because on a monthly basis there is a potential dragon fly bearish, thus a prompt recover toward the upper edge of the bullish flag is important for further climb. I will keep the chart under observation in the next days.
Teva Announce Positive Topline Phase 3 Fasinumab ResultsTEVA: Teva Pharmaceutical Industries Ltd.
2018-08-16 07:00:00
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
TEVA is recharging the battery waiting next earnings release ($TEVA) was accelerating the uptrend but since some days it has come back on its path inside a bullish flag. It is important to note that next week earnings will be released so high volatility should be expected. Masch is about to turn on bullish mode RSI is quite down and vortex is neutral.
I might expect that some investors will get long before the earnings pushing the price up but it is just an hypothesis. So far we are still inside the range with lower and upper edges showed on the chart.
$TEVA LongThis is a pretty simple setup. We have a triple bottom with a strong FL. I feel the r/r here is definitely worth it. The hourly chart looks nice closing above the 13ema. I bought the Aug 25c here. I will set my stop loss at 22.88. Dont forget we also have Buffet buying this stock. Normally i write a longer summary but this set up is pretty easy and visible to all.
TEVA up trend is acceleratingAs showed in the picture trend is accelerating as a sign of streght for TEVA. After some consolidation pauses we have a situation where RSI in pointing up, MACD non really clear as we have had a lateral movement, volatility stop positive.
Red trendline is showing the acceleration. TP around 27 first and 30 dollars after. Despite some up and down of nasdaq, Teva has held the hit continuing the lateral movement rather than going down, another sign of strenght at the moment.
$TEVA - Berkshire breakout? Disclaimer, TEVA is in a very bad financial position, with dwindling cashflows and large debt. Buffet has always been the king of "value investing", hence why a position in Teva isn't surprising from him - it's most likely that he sees the company as severely undervalued and is entering into stages of repair.
Buffet's new position in Teva was widely publicised this week:
fortune.com
markets.businessinsider.com
finance.yahoo.com
Just after Buffet disclosed the position, Teva announced the U.S. release of the QVAR Redihaler Inhalation Aerosol.
www.streetinsider.com
-new form of asthma inhalation treatment
-breath actuated
I don't think this is too important. I'd much rather to follow his other position into AAPL rather than TEVA
Looking good to test the top resistance!This is a longerterm swing trade might be a good option play.
LONG $TEVAFrom looking at the chart patterns, I believe we will see a somewhat classic cup and handle pattern into the next few months. I am anticipating an upward breakout trend now that WB has increased his stake in the company and increases shareholder confidence . After consecutive bad earnings reports I believe this company will recover due to the modest estimates for next quarter. I also think analysts will increase their one year price targets once they have a positive earnings report. In my opinion a good buy and will be buying in next week after markets close Tuesday.
$TEVA LONGMA cross gives the long signal. Plus Warren Buffett bought more so the crowd is jumping on board.
Teva is now a buyAfter a couple of years where price has persistently followed the downtrend, last week Teva broke up such dynamic hreshold. Price has confirmed such trendline with a hammer 3 days ago at 17.04 dollars. Moreover we have the cross on the daily pattern between MA 50 and MA 200 turning to bullish set-up. Q1 earnings has been released beating expectations. SAR is positive and supertrend recently turned into bullish conformation as well. Trump is due to talk about drug prices this week but I don't deem Teva will be harshly impacted, because of the type of business. On a daily basis the hammer of three days ago confirmed by two green candles bear witness to a short term reversal. TP around 21.50/21.80
TEVA: A 5-wave down. Primary count shows A&B completed with CTarget at $27. Alternate count shows ABC completed with wave 1&2 down complete and wave 3 next. Bear trend and no sign of trend change yet.
